CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
disulfiram and chelated zincdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02101008
NCT02101008Phase 2Completed
CompareCT.gov

Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy

University of Utah·interventional·Posted Apr 1, 2014·Updated Dec 13, 2023

In Brief

A Phase 2 clinical trial evaluating disulfiram and chelated zinc for Melanoma. Completed, enrolled 12 participants.

Detailed Summary

Primary Objectives Determine the response rate associated with treatment of refractory disseminated malignant melanoma with disulfiram and chelated zinc. Secondary Objectives Determine the progression-free survival associated with treatment of refractory disseminated malignant melanoma with disulfiram and chelated zinc. Determine the overall survival associated with treatment of refractory disseminated malignant melanoma with disulfiram and chelated zinc. Determine the toxicity associated with treatment of refractory disseminated malignant melanoma with disulfiram and chelated zinc Determine the effect of disulfiram and chelated zinc on in vivo protein S-glutathionylation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 1, 2014
Enrollment StartMar 1, 2010
Primary CompletionFeb 1, 2013
Study CompletionNov 27, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.3 years ago

Interventions

disulfiram and chelated zincdrug